Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154388
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2005-09-09
Brief Title:
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CSTI571B2225
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None